Race‐inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?

Abstract

A real‐world data analysis evaluating the clinical outcomes of consolidation durvalumab after concurrent chemoradiation in Black versus non‐Black patients with unresectable stage III non–small cell lung cancer demonstrates that there was no overall difference in survival or toxicity between the two groups. The study addresses the important issue of race‐ and ethnicity‐related disparities in clinical trial accruals that limit the generalizability of the results across the patient population. Larger multi‐institutional prospective studies evaluating racially underrepresented populations are warranted to evaluate the contribution of individual factors, optimize treatment strategies, and narrow the disparities in cancer care.